

## Programme



**CLINICAL UPDATES ON  
ACUTE LEUKEMIAS**

Budapest, Hungary  
May 4-6, 2018

Chairs : Hervé Dombret, Arnold Ganser, Jorge Sierra, Wendy Stock

**Friday, May 4<sup>th</sup>, 2018**

**SESSION I – Case-based lectures on diagnosis & prognosis**

**Chairs: Robin Foà (Rome), Torsten Haferlach (Munich)**

14:00-14:20	Diagnosis of BCR-ABL1-like ALL	Charles Mullighan (Memphis)
14:20-14:25	<i>Discussion</i>	
14:25-14:45	Bad-prognostic factors in ALL	Nicolas Boissel (Paris)
14:45-14:50	<i>Discussion</i>	
14:50-15:10	ALL diagnosis and classification	Torsten Haferlach (Munich)
15:10-15:15	<i>Discussion</i>	
15:15-15:35	Measurable residual disease in AML	Gert Ossenkoppele (Amsterdam)
15:35-15:40	<i>Discussion</i>	
15:40-16:00	<i>Panel discussion</i>	

**16:00-16:20** *Coffee break*

**16:20-17:20** **ROUNDTABLE I – The origin of leukemic cells**

**Chairs: Charles Mullighan (Memphis), Torsten Haferlach (Munich)**

16:20-16:45	The AML - T-ALL frontier	Elizabeth Macintyre (Paris)
16:45-16:50	<i>Discussion</i>	
16:50-17:15	Leukemic stem cells and their niche	Dominique Bonnet (London)
17:15-17:20	<i>Discussion</i>	
17:20-18:10	<b>DEBATE – Is transplant needed to cure Ph+ ALL in patients who achieve MRD negativity?</b>	
	<b>Chairs: Wendy Stock (Chicago), Hervé Dombret (Paris)</b>	
17:20-17:40	Yes	Oliver Ottmann (Cardiff)
17:40-17:45	<i>Discussion</i>	
17:45-18:05	No	Farhad Ravandi (Houston)
18:05-18:10	<i>Discussion</i>	
18:10-18:30	<b>INTERACTIVE CASE 1</b>	

1

**18:45-20:15** **SATELLITE SYMPOSIUM:**

*This symposium is organized and funded by Jazz Pharmaceuticals*

**20:15-21:30** **Get together and poster viewing (stand up cocktails and buffet dinner for all)**

**Saturday, May 5<sup>th</sup>, 2018**

**07:50-08:50** **Simultaneous Meet the Expert Sessions**

1. How to choose newly approved drugs for relapsed refractory ALL? Nicola Gökbuget (Frankfurt)
2. Optimum management for high risk T-ALL Nicolas Boissel (Paris)
3. How to select the best donor and source for transplantation in younger AML Jorge Sierra (Barcelona)

**SESSION II – Case-based lectures on standard AML therapy**

**Chairs: Nigel Russel (Nottingham), Christoph Röllig (Dresden)**

09:00-09:15	How to use "standard" chemotherapy?	Bek J. Janssens (Dortmund)
-------------	-------------------------------------	----------------------------

07:00-07:15	How to use standard chemotherapy:	DOU LOWENBERG (Nottingham)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Treatment of good ELN risk AML	Jorge Sierra (Barcelona)
09:35-09:40	<i>Discussion</i>	
09:40-09:55	Treatment of poor ELN risk AML	Richard Schlenk (Heidelberg)
09:55-10:00	<i>Discussion</i>	
10:00-10:15	Salvage therapy	Arnold Ganser (Hannover)
10:15-10:20	<i>Discussion</i>	
10:20-10:40	<i>Panel discussion</i>	
<b>10:40-11:10</b>	<b><i>Coffee break</i></b>	

**SESSION III – Case-based lectures on targeted & other therapy in AML**  
**Chairs: Richard Schlenk (Heidelberg), Fehrad Ravandi (Houston)**

11:10-11:25	FLT3 inhibitors	Mark Levis (Baltimore)
11:25-11:30	<i>Discussion</i>	
11:30-11:45	IDH inhibitors	Eytan Stein (New York)
11:45-11:50	<i>Discussion</i>	
11:50-12:05	Arsenic & ATRA in APL	Lionel Ades (Paris)
12:05-12:10	<i>Discussion</i>	
12:10-12:25	Nucleoside analogs	Nigel Russel (Nottingham)
12:25-12:30	<i>Discussion</i>	
12:30-12:45	Gemtuzumab Ozogamicin	Alan Burnett (Isle of Arran)
12:45-12:50	<i>Discussion</i>	
12:50-13:10	<i>Panel discussion</i>	

13:10-14:15 **Lunch**

14:15-14:55 **ROUNDTABLE II – A revival for maintenance therapy in AML?**  
**Chairs: Bob Löwenberg (Rotterdam), Andrew Wei (Melbourne)**

14:15-14:30 Maintenance therapy with targeted agents Christoph Röhlig (Dresden)  
14:30-14:35 *Discussion*

14:35-14:50 Maintenance therapy after transplantation Charles Craddock (Birmingham)  
14:50-14:55 *Discussion*

**SESSION IV – Case-based lectures on older patients with AML**  
**Chairs: Jorge Sierra (Barcelona), Alan Burnett (Isle of Arran)**

14:55-15:10 Low-intensity treatments Hervé Dombret (Paris)  
15:10-15:15 *Discussion*

15:15-15:30 Adding new drugs to low-intensity treatments Gail Roboz (New York)  
15:30-15:35 *Discussion*

15:35-15:50 Targeting cell survival in AML Andrew Wei (Melbourne)  
15:50-15:55 *Discussion*

15:55-16:10 Transplant in older adults Jorge Sierra (Barcelona)  
16:10-16:15 *Discussion*

16:15-16:35 *Panel discussion*

16:35-16:55 **Coffee break**

16:55-17:15 **INTERACTIVE CASE 2**

17:15-17:35 **ROUNDTABLE III – A role for immunotherapy in AML?**  
**Chairs: Gert Ossenkoppele (Amsterdam), Eytan Stein (New York)**

17:15-17:30 Target antigens Marion Subklewe (Munich)  
17:30-17:35 *Discussion*

17:50-19:20 **SATELLITE SYMPOSIUM:**  
*This symposium is organized and funded by Daiichi Sankyo*

**Sunday, May 6, 2018**

**08:00-08:50 Simultaneous Meet the Expert Sessions**

1. How to incorporate new agents into frontline ALL therapy? Wendy Stock (Chicago)
2. How to design novel “novel combination therapy” in AML? Farhad Ravandi (Houston)
3. Have the best reduced intensity conditioning regimen been defined? Charles Craddock (Birmingham)

**SESSION V – Case-based lectures on targeted & immunotherapies in ALL**

**Chairs: Oliver Ottmann (Cardiff), Nicolas Boissel (Paris)**

09:00-09:15	TKI in Ph+ & Ph-like	Robin Foà (Rome)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Antibodies & ADCs	Wendy Stock (Chicago)
09:35-09:40	<i>Discussion</i>	
09:40-09:55	BiTEs	Nicola Gökbuget (Frankfurt)
09:55-10:00	<i>Discussion</i>	
10:00-10:15	CAR T-cells	Noelle Frey (Philadelphia)
10:15-10:20	<i>Discussion</i>	
10:20-10:40	<i>Panel discussion</i>	
<b>10:40-11:00</b>	<b><i>Coffee break</i></b>	
11:00-11:15	Resistance to new immunotherapy	Jae Park (New York)
11:15-11:20	<i>Discussion</i>	
11:20-11:45	Where are we going?	Bob Löwenberg (Rotterdam)
11:45-11:50	<i>Discussion</i>	
<b>11:50-12:00</b>	<b><i>Closing remarks</i></b>	

**MEETING CLOSURE**